The next-generation “GLP-1 plus” drugs will be tailored to the health needs of individual patients.

Novo Nordisk's trial to treat Alzheimer's with its GLP-1 drug failed. The company has been losing market share to Eli Lilly.

U.S. stocks rallied over the trading week, shortened by the Thanksgiving holiday and a reduced trading session on Friday. The ...

Meanwhile, Mercado Envíos (the logistics network) provides faster shipping that boosts customer satisfaction and incentivizes ...

Novo Nordisk ( ($NVO) ) has risen by 8.32%. Read on to learn why. Novo Nordisk’s stock has seen an impressive 8.32% rise over the past week, ...

I also own Eli Lilly, too, so I can handle that pain. Lilly may have the greatest drug franchise of all time with this GLP-1 ...

Things are changing rapidly in the pharmaceutical sector, but Eli Lilly remains in the pole position in weight loss drugs.

To many recent grads, it's a gutting reality check. Shiny tech roles at billion-dollar companies, once sold as tickets to six ...

Some states are rethinking their coverage of GLP-1 drugs for weight loss as budgets tighten and Medicaid programs brace for ...